Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation

被引：0

作者：

Patel, S. ^{[1
]}

Zhao, S. ^{[2
]}

Wei, L. ^{[2
]}

Li, M. ^{[3
]}

Bertino, E. ^{[3
]}

Presley, C. ^{[3
]}

Welliver, M. ^{[3
]}

Haglund, K. ^{[3
]}

Palmer, J. ^{[3
]}

Arnett, A. ^{[3
]}

Beyer, S. ^{[3
]}

Mende, E. ^{[3
]}

Elder, J. ^{[3
]}

Hardesty, D. ^{[3
]}

Shields, P. ^{[4
]}

Carbone, D. ^{[4
]}

Otterson, G. ^{[4
]}

Williams, T. ^{[3
]}

Owen, D. ^{[4
]}

机构：

[1] Ohio State Univ, Ctr Comprehens Canc, Hematol Med Oncol, Columbus, OH 43210 USA

[2] Ohio State Univ, Ctr Comprehens Canc, Biostat, Columbus, OH 43210 USA

[3] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[4] Ohio State Univ, Ctr Comprehens Canc, Med Oncol, Columbus, OH 43210 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期

关键词：

Stage III NSCLC; Brain Metastasis; Durvalumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P21.02

引用

页码：S363 / S364

页数：2

共 50 条

[31] Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
Bischoff, Helge
Garassino, Marina Chiara
Mazieres, Julien
Reck, Martin
Chouaid, Christos
Cove-Smith, Laura
Mansy, Talal
Migliorino, Maria R.
Delmonte, Angelo
Garcia Sanchez, Jose
Chara Velarde, Luis Enrique
Bernabe, Reyes
Paz-Ares, Luis
Perez, Ignacio Diaz
Trunova, Nataliya
Foroutanpour, Kayhan
Faivre-Finn, Corinne
Reinmuth, Niels
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 160 - 161
[32] First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.
Planchard, David
Cho, Byoung Chul
Gray, Jhanelle Elaine
Paz-Ares, Luis G.
Ozguroglu, Mustafa
Villegas, Augusto E.
Daniel, Davey B.
Vicente, David
Murakami, Shuji
Hui, Rina
Kurata, Takayasu
Chiappori, Alberto
Lee, Ki Hyeong
De Wit, Maike
Gu, Yu
Wadsworth, Catherine
Dennis, Phillip A.
Antonia, Scott Joseph
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[33] Early safety assessment of durvalumab after sCRT in patients with stage III, unresectable NSCLC (PACIFIC-6)
Garassino, M. C.
Mazieres, J.
Reck, M.
Delmonte, A.
Bischoff, H. G.
Bernabe, R.
Perez, I. Diaz
Sawyer, W.
Trunova, N.
Faivre-Finn, C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S737 - S737
[34] Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
Garassino, M. C.
Mazieres, J.
Reck, M.
Chouaid, C.
Bischoff, H.
Reinmuth, N.
Cove-Smith, L.
Mansy, T.
Cortinovis, D.
Migliorino, M. R.
Delmonte, A.
Sanchez, J. Garcia
Velarde, L. E. Chara
Bernabe, R.
Paz-Ares, L.
Perez, I. Diaz
Trunova, N.
Foroutanpour, K.
Faivre-Finn, C.
ANNALS OF ONCOLOGY, 2022, 33 : S81 - S82
[35] Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations
Cortiula, Francesco
De Ruysscher, Dirk
Steens, Michelle
Wijsman, Robin
van der Wekken, Anthonie
Alberti, Martina
Hendriks, Lizza E. L.
EUROPEAN JOURNAL OF CANCER, 2023, 184 : 172 - 178
[36] Clinical outcomes in patients with unresectable stage III Non-Small Cell Lung Cancer (NSCLC) treated with durvalumab after chemoradiation in the United Kingdom: CODAK real-world study (NCT04667312)
Franks, Kevin
Smith, Daniel
Shaw, Paul
Banna, Giuseppe Luigi
Cominos, Mathilda
Talbot, Toby
Blak, Betina T.
Lindqvist-Brown, Linnea
Ahmed, Merina
LUNG CANCER, 2024, 190
[37] The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Rueda, Ana Gomez
Taus, Alvaro
Alvarez, Rosa Alvarez
Bernabe-Caro, Reyes
Chara, Luis
Lopez-Brea, Marta
Vila, Laia
Gonzalez, Maria Angeles Sala
Aldagalan, Anabel del Barrio Diaz
Herrera, Beatriz Esteban
Castro, Rafael Lopez
Cabellos, Ruth Alvarez
Domenech, Marta
Falagan, Sandra
Vega, Alberto Moreno
Aguado, Carlos
Barba, Andres
Urena, Maria Teresa Delgado
Isla, Dolores
Hernandez, Lorena Bellido
Perez, Jose Luis Firvida
Juan-Vidal, Oscar
Massuti, Bartomeu
Mielgo-Rubio, Xabier
Ortega, Ana Laura
Catot, Silvia
Domine, Manuel
Escoin-Perez, Corina
Navalon, Francisco Garcia
Gil-Bazo, Ignacio
Munoz, Silvia
Rodriguez-Abreu, Delvys
Roldan, Rosa Maria Villatoro
Curbera, Guillermo Alonso-Jaudenes
Leon-Mateos, Luis
Padilla, Airam
Lario, Alfredo Paredes
Sanchez-Torres, Jose Miguel
Garrido, Pilar
CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (09): : 2205 - 2216
[38] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC
Paz-Ares, L.
Villegas, A.
Daniel, D.
Baz, D. V.
Murakami, S.
Hui, R.
Yokoi, T.
Chiappori, A.
Lee, K. H.
de Wit, M.
Cho, B. C.
Bourhaba, M.
Quantin, X.
Tokito, T.
Mekhail, T.
Planchard, D.
Jiang, H.
Huang, Y.
Dennis, P. A.
Ozguroglu, M.
ANNALS OF ONCOLOGY, 2017, 28
[39] Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
Jazieh, Khalid
Khorrami, Mohammadhadi
Saad, Anas
Gad, Mohamed
Gupta, Amit
Patil, Pradnya
Viswanathan, Vidya Sankar
Rajiah, Prabhakar
Nock, Charles J.
Gilkey, Michael
Fu, Pingfu
Pennell, Nathan A.
Madabhushi, Anant
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
[40] Radiological changes and patterns of progression in unresectable stage III NSCLC treated with concurrent chemoradiotherapy (CCRT) and durvalumab
Patel, Rianne
Abdulwahid, Danya
Bayman, Neil
Coote, Joanna
Cove-Smith, Laura
Fenmore, Jackie
Harris, Margaret
Neal, Hilary
Taylor, Paul
Sheikh, Hamid
Woolf, David
Chan, Clara
Faivre-Finn, Corinee
LUNG CANCER, 2023, 178 : S59 - S59

← 1 2 3 4 5 →